Patents by Inventor Christopher Carlin Valley

Christopher Carlin Valley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using
    Patent number: 11897958
    Abstract: Described herein are monoclonal antibodies that bind to VSIG-4 including antibodies that block the binding of VSIG-4 to SIGLEC-7, compositions including the monoclonal antibodies, and methods of making and using those antibodies and compositions.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: February 13, 2024
    Assignee: BIO-TECHNE CORPORATION
    Inventors: Birte Aggeler, Christine Goetz, Jody Bonnevier, Christopher Carlin Valley, Christopher Hammerbeck, Ernesto Ruben Resnik
  • Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
    Patent number: 11649285
    Abstract: The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: May 16, 2023
    Assignee: BIO-TECHNE CORPORATION
    Inventors: Vassilios Kalabokis, Jinghua Wang, Guoping Wu, Jose Fernando Bazan, Christopher Carlin Valley
  • HYBRIDOMA CLONES, MONOCLONAL ANTIBODIES TO VSIG-4, AND METHODS OF MAKING AND USING
    Publication number: 20210087276
    Abstract: Described herein are monoclonal antibodies that bind to VSIG-4 including antibodies that block the binding of VSIG-4 to SIGLEC-7, compositions including the monoclonal antibodies, and methods of making and using those antibodies and compositions.
    Type: Application
    Filed: August 19, 2020
    Publication date: March 25, 2021
    Inventors: Birte Aggeler, Christine Goetz, Jody Bonnevier, Christopher Carlin Valley, Christopher Hammerbeck, Ernesto Ruben Resnik
  • Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using
    Patent number: 10752689
    Abstract: Described herein are monoclonal antibodies that bind to VSIG-4 including antibodies that block the binding of VSIG-4 to SIGLEC-7, compositions including the monoclonal antibodies, and methods of making and using those antibodies and compositions.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: August 25, 2020
    Assignee: BIO-TECHNE CORPORATION
    Inventors: Birte Aggeler, Christine Goetz, Jody Bonnevier, Christopher Carlin Valley, Chris Hammerbeck, Ernesto Ruben Resnik
  • IDENTIFICATION OF VSIG3/VISTA AS A NOVEL IMMUNE CHECKPOINT AND USE THEREOF FOR IMMUNOTHERAPY
    Publication number: 20190194322
    Abstract: The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG/3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.
    Type: Application
    Filed: August 3, 2017
    Publication date: June 27, 2019
    Applicant: BIO-TECHNE CORPORATION
    Inventors: Vassilios Kalabokis, Jinghua Wang, Guoping Wu, Jose Fernando Bazan, Christopher Carlin Valley
  • HYBRIDOMA CLONES, MONOCLONAL ANTIBODIES TO VSIG-4, AND METHODS OF MAKING AND USING
    Publication number: 20180371095
    Abstract: Described herein are monoclonal antibodies that bind to VSIG-4 including antibodies that block the binding of VSIG-4 to SIGLEC-7, compositions including the monoclonal antibodies, and methods of making and using those antibodies and compositions.
    Type: Application
    Filed: June 26, 2018
    Publication date: December 27, 2018
    Inventors: Birte Aggeler, Christine Goetz, Jody Bonnevier, Christopher Carlin Valley, Chris Hammerbeck